TYRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tyra Biosciences Inc (TYRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support, promising drug development with significant potential upside, and favorable long-term growth prospects. Despite some insider selling and lack of immediate trading signals, the long-term outlook and catalysts make it a compelling investment.
The MACD is negative (-0.51) but contracting, RSI is neutral at 34.717, and moving averages are converging. The stock is trading near its support level (S1: 34.961), with resistance at R1: 39.507. This suggests limited downside risk and potential for upward movement.
Promising drug development pipeline with dabogratinib showing potential to become a standard of care in multiple indications. High probability of positive returns in the next week (3.92%) and month (8.16%).
Insider selling has increased significantly (100.98%) over the last month, which may indicate some caution from insiders. No recent news or congress trading data to provide additional confidence.
In Q4 2025, the company reported no revenue but showed improvement in net income (-$33.83M, up 32.31% YoY) and EPS (-$0.57, up 32.56% YoY). While still unprofitable, the financials indicate progress in reducing losses.
Analysts are overwhelmingly positive, with multiple Buy ratings and price targets as high as $59.62. They highlight the company's innovative drug pipeline and potential blockbuster opportunities for dabogratinib.
